Advanced Solid Tumors Clinical Trials

248 recruitingLast updated: June 17, 2026

There are 248 actively recruiting advanced solid tumors clinical trials across 40 countries. Studies span Phase 1, Phase 2, Early Phase 1, Not Applicable. Top locations include Houston, Texas, United States, Shanghai, Shanghai Municipality, China, Beijing, Beijing Municipality, China. Updated daily from ClinicalTrials.gov.


Advanced Solid Tumors Trials at a Glance

248 actively recruiting trials for advanced solid tumors are listed on ClinicalTrialsFinder across 6 cities in 40 countries. The largest study group is Phase 1 with 216 trials, with the heaviest enrollment activity in Houston, Shanghai, and Beijing. Lead sponsors running advanced solid tumors studies include Jiangsu HengRui Medicine Co., Ltd., Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., and Shanghai Hengrui Pharmaceutical Co., Ltd..

Browse advanced solid tumors trials by phase

Treatments under study

About Advanced Solid Tumors Clinical Trials

Looking for clinical trials for Advanced Solid Tumors? There are currently 199 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Advanced Solid Tumors trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Advanced Solid Tumors clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 248 trials

Recruiting
Phase 1

Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors

Advanced Breast CancerAdvanced Solid TumorsMetastatic Pancreatic Cancer+3 more
National Cancer Institute (NCI)116 enrolled2 locationsNCT04222413
Recruiting
Phase 1

Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001)

Advanced Solid TumorsMetastatic Solid Tumors
Merck Sharp & Dohme LLC178 enrolled25 locationsNCT05853367
Recruiting
Phase 1

A Study of the Safety and Efficacy of the Intravenous and Intratumoral Injection of OVV-01 in Patients With Advanced Solid Tumours.

Advanced Solid Tumors
Joint Biosciences Ltd.18 enrolled1 locationNCT07648472
Recruiting
Phase 1Phase 2

Study of CM518D1 in Patients With Advanced Solid Tumors

Advanced Solid Tumors
Keymed Biosciences Co.Ltd434 enrolled1 locationNCT07019779
Recruiting
Phase 1

Leflunomide in Patients With PTEN-Altered Advanced Solid Malignancies and HER2 Negative Breast Cancer

PTEN-Altered Advanced Solid Tumors and HER2 Negative Breast Cancer
Deborah Doroshow23 enrolled1 locationNCT04997993
Recruiting
Phase 1

Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors

Advanced Solid Tumors
EMD Serono Research & Development Institute, Inc.138 enrolled9 locationsNCT07360314
Recruiting
Phase 1

AMG 436 as Monotherapy and Combination Therapy in Participants With MSI-H/dMMR Solid Tumors

Metastatic or Locally Advanced Solid Tumors With Microsatellite Instability-high (MSI-H) or Mismatched Repair Deficiency (dMMR)
Amgen464 enrolled16 locationsNCT07403721
Recruiting
Phase 1Phase 2

A Study of AZD3470, a PRMT5 Inhibitor, Given as Monotherapy and in Combination in Patients With MTAP Deficient Advanced/Metastatic Solid Tumors

Advanced Solid Tumors That Are MTAP Deficient
AstraZeneca334 enrolled21 locationsNCT06130553
Recruiting
Phase 1Phase 2

Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments

Locally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung CancerAdvanced Solid Tumors Harboring the KRAS G12C Mutation
Novartis Pharmaceuticals40 enrolled1 locationNCT07468071
Recruiting
Phase 1

A Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Rilvegostomig in Adult Participants With Advanced Solid Tumors Previously Treated With Standard of Care Therapy

Advanced Solid Tumors
AstraZeneca40 enrolled11 locationsNCT07161414
Recruiting
Phase 1

A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations

CancerAdvanced Solid TumorsNSCLC (Non-small Cell Lung Cancer)+2 more
Alterome Therapeutics, Inc.448 enrolled12 locationsNCT06835569
Recruiting
Phase 1

A Study to Evaluate the Mass Balance, Metabolism, Elimination, and Drug Levels of [14C]-BMS-986504 (MRTX1719) in Participants With Advanced Solid Tumors With Homozygous Methylthioadenosine Phosphorylase Deletion

Advanced Solid Tumors With Homozygous MTAP Deletion
Bristol-Myers Squibb8 enrolled3 locationsNCT06672523
Recruiting
Phase 1

A Study of JNJ-87890387 for Advanced Solid Tumors

Advanced Solid TumorsNeoplasms
Janssen Research & Development, LLC200 enrolled6 locationsNCT06178614
Recruiting
Phase 1Phase 2

A Phase 1/2 Study of D3S-002 as Monotherapy or Combination Therapy in Adult Subjects With Advanced Solid Tumors With MAPK Pathway Mutations

Advanced Solid Tumors With MAPK Pathway Mutations
D3 Bio (Wuxi) Co., Ltd67 enrolled14 locationsNCT05886920
Recruiting
Phase 1

A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors

Colorectal, CancerAdvanced Solid Tumors
Vividion Therapeutics, Inc.280 enrolled29 locationsNCT06004245
Recruiting
Phase 1

A Study of BG-C477 in Participants With Advanced Solid Tumors

Advanced Solid Tumors
BeOne Medicines310 enrolled52 locationsNCT06596473
Recruiting
Phase 1

A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors

Endometrial CancerHER2-low Breast CancerHR Positive/HER-2 Negative Breast Cancer+2 more
Cogent Biosciences, Inc.90 enrolled2 locationsNCT07383506
Recruiting
Phase 1

A Study of PHN-012 in Patients With Advanced Solid Tumors

Pancreatic CancerColon CancerAdvanced Cancer+2 more
Pheon Therapeutics165 enrolled20 locationsNCT07127874
Recruiting
Phase 2

A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

Advanced Solid TumorsHER2 Mutation
Bayer111 enrolled54 locationsNCT06760819
Recruiting
Phase 1

Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors

Non-small Cell Lung Cancer (NSCLC)Pancreatic Ductal Adenocarcinoma (PDAC)Advanced Solid Tumors+1 more
Revolution Medicines, Inc.604 enrolled17 locationsNCT06040541